{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:53:00Z","timestamp":1791755580283,"version":"4.3.4"},"reference-count":292,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["19 0359 Pj"],"award-info":[{"award-number":["19 0359 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["CAN 2017\/383"],"award-info":[{"award-number":["CAN 2017\/383"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2019-01541"],"award-info":[{"award-number":["2019-01541"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Cancer Research Foundations of Radiumhemmet","doi-asserted-by":"publisher","award":["191222"],"award-info":[{"award-number":["191222"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007232","name":"Cancer Research Foundations of Radiumhemmet","doi-asserted-by":"publisher","award":["201232"],"award-info":[{"award-number":["201232"]}],"id":[{"id":"10.13039\/501100007232","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["21 1562 Fk"],"award-info":[{"award-number":["21 1562 Fk"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","award":["216113"],"award-info":[{"award-number":["216113"]}],"id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semcancer.2022.03.027","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T16:32:15Z","timestamp":1649176335000},"page":"207-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":173,"special_numbering":"P3","title":["Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment"],"prefix":"10.1016","volume":"86","author":[{"given":"Esther","family":"Schoutrop","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Moyano-Galceran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaisa","family":"Lehti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Dahlstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Magalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2022.03.027_bib1","unstructured":"N. s. D. o. C. C. a. P. Sciences, SEER cancer statistics: Ovarian cancer. (2017)."},{"key":"10.1016\/j.semcancer.2022.03.027_bib2","unstructured":"F. Reid, \"WORLD OVARIAN CANCER. COALITION ATLAS 2020,\" (World ovarian cancer coalition, 2020)."},{"key":"10.1016\/j.semcancer.2022.03.027_bib3","first-page":"284","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA: A Cancer J. Clin."},{"key":"10.1016\/j.semcancer.2022.03.027_bib4","unstructured":"P.D. Q.A. T.E. Board, in PDQ Cancer Information Summaries. (National Cancer Institute (US), Bethesda (MD), 2002)."},{"key":"10.1016\/j.semcancer.2022.03.027_bib5","first-page":"925","article-title":"Mechanisms of transcoelomic metastasis in ovarian cancer. The Lancet","volume":"7","author":"Tan","year":"2006","journal-title":"Oncology"},{"key":"10.1016\/j.semcancer.2022.03.027_bib6","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00404-018-4952-9","article-title":"Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015","volume":"299","author":"Krugmann","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.semcancer.2022.03.027_bib7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/OTT.S155425","article-title":"First-line treatment of women with advanced ovarian cancer: Focus on bevacizumab","volume":"12","author":"Marchetti","year":"2019","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.semcancer.2022.03.027_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib9","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib10","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.semcancer.2022.03.027_bib11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib12","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis: Revisited, revised, and expanded","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0002-9440(10)63708-X","article-title":"Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis","volume":"164","author":"Shih","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib14","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00404-016-4035-8","article-title":"The new WHO classification of ovarian, fallopian tube, and primary peritoneal cancer and its clinical implications","volume":"293","author":"Meinhold-Heerlein","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.semcancer.2022.03.027_bib15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","article-title":"Differences in tumor type in low-stage versus high-stage ovarian carcinomas","volume":"29","author":"K\u00f6bel","year":"2010","journal-title":"Int. J. Gynecol. Pathol.: Off. J. Int. Soc. Gynecol. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2022.03.027_bib17","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","article-title":"Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"397","author":"Menon","year":"2021","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.semcancer.2022.03.027_bib18","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAS.0b013e3181cf3d79","article-title":"Ie, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib20","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/PAS.0b013e3181868904","article-title":"Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?","volume":"33","author":"Roh","year":"2009","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib21","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1158\/1078-0432.CCR-04-2509","article-title":"Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon","volume":"11","author":"Marquez","year":"2005","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2022.03.027_bib22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ygyno.2010.11.020","article-title":"\u201cPrimary peritoneal\u201d high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer","volume":"120","author":"Seidman","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib23","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1038\/s41467-019-13116-2","article-title":"Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma","volume":"10","author":"Zhang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.03.027_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.03.027_bib25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ygyno.2019.08.029","article-title":"Defining the molecular evolution of extrauterine high grade serous carcinoma","volume":"155","author":"Beirne","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010358","article-title":"Genetic analysis of the early natural history of epithelial ovarian carcinoma","volume":"5","author":"Pothuri","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.semcancer.2022.03.027_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/PGP.0000000000000120","article-title":"Two types of ovarian cortical inclusion cysts: proposed origin and possible role in ovarian serous carcinogenesis","volume":"34","author":"Banet","year":"2015","journal-title":"Int. J. Gynecol. Pathol.: Off. J. Int. Soc. Gynecol. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib28","doi-asserted-by":"crossref","first-page":"12645","DOI":"10.1038\/ncomms12645","article-title":"Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status","volume":"7","author":"Coscia","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.03.027_bib29","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1158\/1078-0432.CCR-17-0638","article-title":"Integrated Analysis Reveals Tubal- and Ovarian-Originated Serous Ovarian Cancer and Predicts Differential Therapeutic Responses","volume":"23","author":"Hao","year":"2017","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2022.03.027_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2022.03.027_bib31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv214","article-title":"Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer","volume":"107","author":"Ramus","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.semcancer.2022.03.027_bib33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.955","article-title":"Mutations in BRIP1 confer high risk of ovarian cancer","volume":"43","author":"Rafnar","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2022.03.027_bib34","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/cncr.11770","article-title":"Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma","volume":"98","author":"Geisler","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib35","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.7150\/jca.30410","article-title":"The role in genome stability, cancer stemness and therapy resistance","volume":"10","author":"Gorodetska","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.tips.2010.06.001","article-title":"Targeting homologous recombination repair defects in cancer","volume":"31","author":"Evers","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib37","doi-asserted-by":"crossref","first-page":"16906","DOI":"10.1073\/pnas.0809380105","article-title":"Human exonuclease 1 and BLM helicase interact to resect DNA and initiate DNA repair","volume":"105","author":"Nimonkar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.semcancer.2022.03.027_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122930","article-title":"Regulation of RAD51 at the transcriptional and functional levels: What prospects for cancer therapy?","volume":"13","author":"Orhan","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2022.03.027_bib39","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib40","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-17-3770","article-title":"A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients","volume":"24","author":"Tumiati","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib41","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013366","article-title":"Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer","volume":"13","author":"Hoppe","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib42","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2016.08.320","article-title":"Low-grade serous ovarian cancer: A review","volume":"143","author":"Kaldawy","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib43","first-page":"13","article-title":"Tubal origin of ovarian low-grade serous carcinoma","volume":"1","author":"Chen","year":"2013","journal-title":"Am. J. Clin. Exp. Obstet. Gynecol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/PAT.0b013e32835f2264","article-title":"Precursors and pathogenesis of ovarian carcinoma","volume":"45","author":"Lim","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.semcancer.2022.03.027_bib45","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.semcancer.2022.03.027_bib46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1055\/s-0036-1597120","article-title":"Cancer implications for patients with endometriosis","volume":"35","author":"Wilbur","year":"2017","journal-title":"Semin. Reprod. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib47","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ygyno.2017.02.022","article-title":"Genetic risk factors for ovarian cancer and their role for endometriosis risk","volume":"145","author":"Burghaus","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib49","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/gyno.2001.6279","article-title":"The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer","volume":"82","author":"Watson","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib50","first-page":"g8","article-title":"Ovarian cancer: natural history and metastatic pattern","volume":"2","author":"Amadori","year":"1997","journal-title":"Front. Biosci. J. Virtual Libr."},{"key":"10.1016\/j.semcancer.2022.03.027_bib51","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int. J. Gynaecol. Obstet.: Off. Organ Int. Fed. Gynaecol. Obstet."},{"key":"10.1016\/j.semcancer.2022.03.027_bib53","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2020.09.002","article-title":"The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration","volume":"159","author":"Gunay","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib54","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1038\/s41388-018-0317-x","article-title":"Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer","volume":"37","author":"Al Habyan","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2022.03.027_bib55","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1242\/bio.2012653","article-title":"Spontaneous spheroid budding from monolayers: A potential contribution to ovarian cancer dissemination","volume":"1","author":"Pease","year":"2012","journal-title":"Biol. Open"},{"key":"10.1016\/j.semcancer.2022.03.027_bib56","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1038\/onc.2014.264","article-title":"Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells","volume":"34","author":"Cai","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2022.03.027_bib57","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1038\/nm1125","article-title":"The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers","volume":"10","author":"Cheng","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib58","first-page":"4837","article-title":"Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L)","volume":"61","author":"Frankel","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib59","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1158\/0008-5472.CAN-09-3557","article-title":"Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells","volume":"70","author":"He","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib60","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/1878-0261.12845","article-title":"Constitutive activation of integrin \u03b1v\u03b23 contributes to anoikis resistance of ovarian cancer cells","volume":"15","author":"Dolinschek","year":"2021","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbrc.2021.05.008","article-title":"Angiopoietin-like protein 2 decreases peritoneal metastasis of ovarian cancer cells by suppressing anoikis resistance","volume":"561","author":"Takeshita","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.semcancer.2022.03.027_bib62","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2017.06.008","article-title":"Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study","volume":"146","author":"Szender","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib63","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1136\/ijgc-2021-002978","article-title":"Ascites volume at the time of primary debulking and overall survival of patients with advanced epithelial ovarian cancer","volume":"31","author":"Nasioudis","year":"2021","journal-title":"Int. J. Gynecol. Cancer: Off. J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.semcancer.2022.03.027_bib64","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/jog.14682","article-title":"Relationship between ascites volume and clinical outcomes in epithelial ovarian cancer","volume":"47","author":"Quan","year":"2021","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib65","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","article-title":"Malignant ascites: past, present, and future","volume":"198","author":"Adam","year":"2004","journal-title":"J. Am. Coll. Surg."},{"key":"10.1016\/j.semcancer.2022.03.027_bib66","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/cas.12987","article-title":"Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer","volume":"107","author":"Kim","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrc3432","article-title":"Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research","volume":"13","author":"Kipps","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib68","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fonc.2017.00024","article-title":"The unique molecular and cellular microenvironment of ovarian cancer","volume":"7","author":"Worzfeld","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib69","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191094","article-title":"Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21","volume":"217","author":"Hussain","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib70","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1084\/jem.20180765","article-title":"Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer","volume":"216","author":"Gao","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2011.01.011","article-title":"Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion","volume":"303","author":"Zhang","year":"2011","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2022.03.027_bib72","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/carcin\/bgr230","article-title":"Fibroblasts in omentum activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness","volume":"33","author":"Cai","year":"2012","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.semcancer.2022.03.027_bib73","first-page":"2245","article-title":"Tumor cell\u2011fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer","volume":"44","author":"Han","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib74","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-12-0206","article-title":"MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer","volume":"2","author":"Mitra","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2022.03.027_bib75","doi-asserted-by":"crossref","first-page":"4157","DOI":"10.1172\/JCI87252","article-title":"Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer","volume":"126","author":"Yin","year":"2016","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.semcancer.2022.03.027_bib76","doi-asserted-by":"crossref","first-page":"11913","DOI":"10.1038\/s41598-020-68639-2","article-title":"Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer","volume":"10","author":"Asem","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2022.03.027_bib77","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/nrc1611","article-title":"Ovarian cancer metastasis: Integrating insights from disparate model organisms","volume":"5","author":"Naora","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060965","article-title":"Fluid-flow induced wall shear stress and epithelial ovarian cancer peritoneal spreading","volume":"8","author":"Avraham-Chakim","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.semcancer.2022.03.027_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9040924","article-title":"Flow-induced shear stress confers resistance to carboplatin in an adherent three-dimensional model for ovarian cancer: A role for EGFR-targeted photoimmunotherapy informed by physical stress","volume":"9","author":"Nath","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib80","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1006\/gyno.1998.5215","article-title":"Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer","volume":"71","author":"Gotlieb","year":"1998","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib81","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00464-008-0041-7","article-title":"Molecular mechanisms underlying postoperative peritoneal tumor dissemination may differ between a laparotomy and carbon dioxide pneumoperitoneum: a syngeneic mouse model with controlled respiratory support","volume":"23","author":"Matsuzaki","year":"2009","journal-title":"Surg. Endosc."},{"key":"10.1016\/j.semcancer.2022.03.027_bib82","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003295","article-title":"The diagnostic performance of CA125 for the detection of ovarian and non-ovarian cancer in primary care: A population-based cohort study","volume":"17","author":"Funston","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib84","article-title":"Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses","volume":"98","author":"Zheng","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.semcancer.2022.03.027_bib85","doi-asserted-by":"crossref","first-page":"27371","DOI":"10.1074\/jbc.M103554200","article-title":"Molecular cloning of the CA125 ovarian cancer antigen: Identification as a new mucin, MUC16","volume":"276","author":"Yin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2022.03.027_bib86","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s12325-020-01520-w","article-title":"Mesothelin expression in patients with high-grade serous ovarian cancer does not predict clinical outcome but correlates with CD11c(+) expression in tumor","volume":"37","author":"Magalhaes","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.semcancer.2022.03.027_bib87","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1078-0432.CCR-05-1397","article-title":"Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma","volume":"12","author":"Yen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040397","article-title":"Mesothelin expression in human tumors: A tissue microarray study on 12,679 tumors","volume":"9","author":"Weidemann","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.semcancer.2022.03.027_bib89","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib90","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41389-020-00246-2","article-title":"Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation","volume":"9","author":"Coelho","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.semcancer.2022.03.027_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19072045","article-title":"Mucins and truncated O-Glycans unveil phenotypic discrepancies between serous ovarian cancer cell lines and primary tumours","volume":"19","author":"Coelho","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib92","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212443","article-title":"Host mesothelin expression increases ovarian cancer metastasis in the peritoneal microenvironment","volume":"22","author":"Hilliard","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib93","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/S0002-9440(10)63058-1","article-title":"Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids","volume":"159","author":"Casey","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib94","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","article-title":"Every step of the way: integrins in cancer progression and metastasis","volume":"18","author":"Hamidi","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib95","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000024495","article-title":"Metastatic dissemination of human ovarian epithelial carcinoma is promoted by alpha2beta1-integrin-mediated interaction with type I collagen","volume":"18","author":"Fishman","year":"1998","journal-title":"Invasion Metastas-.-."},{"key":"10.1016\/j.semcancer.2022.03.027_bib96","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/onc.2010.532","article-title":"Ligand-independent activation of c-Met by fibronectin and \u03b1(5)\u03b2(1)-integrin regulates ovarian cancer invasion and metastasis","volume":"30","author":"Mitra","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.semcancer.2022.03.027_bib97","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1515\/BC.2003.120","article-title":"Ovarian cancer cell proliferation and motility is induced by engagement of integrin alpha(v)beta3\/Vitronectin interaction","volume":"384","author":"Hapke","year":"2003","journal-title":"Biol. Chem."},{"key":"10.1016\/j.semcancer.2022.03.027_bib98","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.18632\/aging.102954","article-title":"Overexpressed ITGA2 contributes to paclitaxel resistance by ovarian cancer cells through the activation of the AKT\/FoxO1 pathway","volume":"12","author":"Ma","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.semcancer.2022.03.027_bib99","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.59442","article-title":"Collagen-rich omentum is a premetastatic niche for integrin \u03b12-mediated peritoneal metastasis","volume":"9","author":"Huang","year":"2020","journal-title":"eLife"},{"key":"10.1016\/j.semcancer.2022.03.027_bib100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41389-020-00254-2","article-title":"The identification of nuclear \u03b1v\u03b23 integrin in ovarian cancer: non-paradigmal localization with cancer promoting actions","volume":"9","author":"Seraya-Bareket","year":"2020","journal-title":"Oncogenesis"},{"key":"10.1016\/j.semcancer.2022.03.027_bib101","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nsmb.3161","article-title":"Selective integrin endocytosis is driven by interactions between the integrin \u03b1-chain and AP2","volume":"23","author":"De Franceschi","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib102","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.tcb.2016.02.001","article-title":"Endosomes: Emerging platforms for integrin-mediated FAK signalling","volume":"26","author":"Alanko","year":"2016","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib103","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.03.027_bib104","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/j.bbamcr.2017.04.002","article-title":"Membrane-type matrix metalloproteases as diverse effectors of cancer progression","volume":"1864","author":"Turunen","year":"2017","journal-title":"Biochim. Et. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib105","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10585-014-9658-1","article-title":"Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on \u03b1v integrins","volume":"31","author":"Carduner","year":"2014","journal-title":"Clin. Exp. Metastas."},{"key":"10.1016\/j.semcancer.2022.03.027_bib106","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/path.4889","article-title":"Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer","volume":"242","author":"Rynne-Vidal","year":"2017","journal-title":"J. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib107","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1158\/1078-0432.CCR-05-2338","article-title":"The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer","volume":"12","author":"Kamat","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.semcancer.2022.03.027_bib109","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1023\/A:1006723011835","article-title":"High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma","volume":"17","author":"Davidson","year":"1999","journal-title":"Clin. Exp. Metastas-.-."},{"key":"10.1016\/j.semcancer.2022.03.027_bib110","doi-asserted-by":"crossref","DOI":"10.1177\/0300060519825983","article-title":"The prognostic values of matrix metalloproteinases in ovarian cancer","volume":"48","author":"Zeng","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib111","first-page":"2396","article-title":"Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer","volume":"7","author":"Schmalfeldt","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib112","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1006\/gyno.2001.6243","article-title":"Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer","volume":"82","author":"Lengyel","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib113","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00404-016-4257-9","article-title":"Prognostic value of MMP-2 for patients with ovarian epithelial carcinoma: A systematic review and meta-analysis","volume":"295","author":"Jia","year":"2017","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.semcancer.2022.03.027_bib114","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13000-016-0485-3","article-title":"Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer","volume":"11","author":"Vos","year":"2016","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib115","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.21873\/anticanres.13289","article-title":"MMP-2 mRNA expression in ovarian cancer tissues predicts patients\u2019 response to platinum-taxane chemotherapy","volume":"39","author":"Jeleniewicz","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib116","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13048-020-00676-x","article-title":"Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors","volume":"13","author":"Morales-V\u00e1squez","year":"2020","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib117","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/IGC.0000000000000386","article-title":"The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer","volume":"25","author":"Fu","year":"2015","journal-title":"Int. J. Gynecol. Cancer: Off. J. Int. Gynecol. Cancer Soc."},{"key":"10.1016\/j.semcancer.2022.03.027_bib118","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13048-021-00852-7","article-title":"The role of MMP-14 in ovarian cancer: a systematic review","volume":"14","author":"Vos","year":"2021","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib119","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/0008-5472.CAN-08-4151","article-title":"Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination","volume":"69","author":"Moss","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib120","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-12-1426","article-title":"Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer","volume":"73","author":"Kaimal","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib121","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.actbio.2021.04.041","article-title":"Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model","volume":"132","author":"Horst","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.semcancer.2022.03.027_bib122","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12026-009-8100-2","article-title":"Omental immune aggregates and tumor metastasis within the peritoneal cavity","volume":"45","author":"Sorensen","year":"2009","journal-title":"Immunol. Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib123","first-page":"687","article-title":"Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice","volume":"53","author":"Hagiwara","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib124","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.500","article-title":"Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma","volume":"11","author":"Hao","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"1755\u20131769","key":"10.1016\/j.semcancer.2022.03.027_bib126","article-title":"Interfaces of malignant and immunologic clonal dynamics in ovarian cancer","volume":"173","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2022.03.027_bib127","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002873","article-title":"Immunological configuration of ovarian carcinoma: features and impact on disease outcome","volume":"9","author":"Fucikova","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"928\u2013944","key":"10.1016\/j.semcancer.2022.03.027_bib128","article-title":"Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer","volume":"39","author":"Hornburg","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2022.03.027_bib129","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1535730","article-title":"Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer","volume":"8","author":"R\u00e5destad","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2022.03.027_bib131","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib132","doi-asserted-by":"crossref","first-page":"18538","DOI":"10.1073\/pnas.0509182102","article-title":"Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer","volume":"102","author":"Sato","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.semcancer.2022.03.027_bib133","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib134","first-page":"2875","article-title":"Ovarian cancer-associated ascites demonstrates altered immune environment: Implications for antitumor immunity","volume":"29","author":"Giuntoli","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ygyno.2007.02.029","article-title":"Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance","volume":"106","author":"Bamias","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib136","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1242\/jcs.116392","article-title":"The tumor microenvironment at a glance","volume":"125","author":"Balkwill","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib137","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","article-title":"Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients","volume":"64","author":"Landskron","year":"2015","journal-title":"Cancer Immunol. Immunother. CII"},{"key":"10.1016\/j.semcancer.2022.03.027_bib138","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/1471-2407-11-210","article-title":"Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients","volume":"11","author":"Lane","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib139","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.3389\/fimmu.2017.01482","article-title":"Interleukin 6 present in inflammatory ascites from advanced epithelial ovarian cancer patients promotes tumor necrosis factor Receptor 2-expressing regulatory T cells","volume":"8","author":"Kampan","year":"2017","journal-title":"Front Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib140","first-page":"566","article-title":"Profiling of cytokines in human epithelial ovarian cancer ascites","volume":"2","author":"Matte","year":"2012","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib141","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1006\/cimm.1996.0301","article-title":"HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2","volume":"174","author":"Kooi","year":"1996","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib142","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1158\/1078-0432.CCR-08-0479","article-title":"Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer","volume":"14","author":"Callahan","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib143","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coi.2018.03.006","article-title":"The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses","volume":"51","author":"Aptsiauri","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib144","first-page":"6457","article-title":"Expression of multiple immune checkpoint molecules on T cells in malignant ascites from epithelial ovarian carcinoma","volume":"15","author":"Imai","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.semcancer.2022.03.027_bib145","doi-asserted-by":"crossref","unstructured":"J. Duraiswamy et al., Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation. Cancer cell, (2021).","DOI":"10.1016\/j.ccell.2021.10.008"},{"key":"10.1016\/j.semcancer.2022.03.027_bib146","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1158\/1078-0432.CCR-20-4394","article-title":"Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes coexpressing CD39, CD103, and PD-1 in ovarian cancer","volume":"27","author":"Laumont","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2022.03.027_bib147","series-title":"Basic Immunology: Functions and Disorders of the Immune System","author":"Abul","year":"2016"},{"key":"10.1016\/j.semcancer.2022.03.027_bib148","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb0192","article-title":"Characterization of ascites- and tumor-infiltrating \u03b3\u03b4 T cells reveals distinct repertoires and a beneficial role in ovarian cancer","volume":"13","author":"Foord","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib149","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41568-019-0153-5","article-title":"\u03b3\u03b4 T cells: Pleiotropic immune effectors with therapeutic potential in cancer","volume":"19","author":"Silva-Santos","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib150","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","article-title":"The role of natural killer T cells in cancer-a phenotypical and functional approach","volume":"9","author":"Krijgsman","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib151","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1158\/1078-0432.CCR-05-0877","article-title":"Increased intratumor Valpha24-positive natural killer T cells: A prognostic factor for primary colorectal carcinomas","volume":"11","author":"Tachibana","year":"2005","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2022.03.027_bib152","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00383-017-4189-x","article-title":"Invariant natural killer T infiltration in neuroblastoma with favorable outcome","volume":"34","author":"Hishiki","year":"2018","journal-title":"Pediatr. Surg. Int."},{"key":"10.1016\/j.semcancer.2022.03.027_bib153","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1471-0528.2004.00142.x","article-title":"Increased levels of gangliosides in the plasma and ascitic fluid of patients with advanced ovarian cancer","volume":"111","author":"Santin","year":"2004","journal-title":"BJOG: Int. J. Obstet. Gynaecol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib154","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1158\/0008-5472.CAN-11-2695","article-title":"Molecular identification of GD3 as a suppressor of the innate immune response in ovarian cancer","volume":"72","author":"Webb","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib155","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: Therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.semcancer.2022.03.027_bib156","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coi.2017.01.002","article-title":"Dendritic cells in cancer: The role revisited","volume":"45","author":"Veglia","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib157","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/nm1201-1339","article-title":"Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells","volume":"7","author":"Zou","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib158","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejca.2020.04.036","article-title":"Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer","volume":"135","author":"Mastelic-Gavillet","year":"2020","journal-title":"Eur. J. Cancer (Oxf., Engl.: 1990)"},{"key":"10.1016\/j.semcancer.2022.03.027_bib159","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1084\/jem.20111413","article-title":"Ovarian cancer progression is controlled by phenotypic changes in dendritic cells","volume":"209","author":"Scarlett","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib160","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.celrep.2016.01.056","article-title":"Satb1 overexpression drives tumor-promoting activities in cancer-associated dendritic cells","volume":"14","author":"Tesone","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2022.03.027_bib161","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.3389\/fimmu.2018.03156","article-title":"Survival of ovarian cancer patients is independent of the presence of DC and T cell subsets in ascites","volume":"9","author":"Wefers","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib162","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.1158\/0008-5472.CAN-11-0367","article-title":"Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer","volume":"71","author":"Labidi-Galy","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020305","article-title":"Opposite macrophage polarization in different subsets of ovarian cancer: Observation from a pilot study","volume":"9","author":"Vankerckhoven","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2022.03.027_bib164","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage polarization: Different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib165","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage polarization","volume":"79","author":"Murray","year":"2017","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib166","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","article-title":"Tumor-associated macrophages: An accomplice in solid tumor progression","volume":"26","author":"Chen","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib167","doi-asserted-by":"crossref","first-page":"48436","DOI":"10.18632\/oncotarget.17061","article-title":"Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy","volume":"8","author":"Zheng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2022.03.027_bib168","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1158\/0008-5472.CAN-21-0536","article-title":"TGFBI production by macrophages contributes to an immunosuppressive microenvironment in ovarian cancer","volume":"81","author":"Lecker","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib169","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fonc.2014.00137","article-title":"Tumor-associated macrophages contribute to tumor progression in ovarian cancer","volume":"4","author":"Colvin","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib170","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/j.1349-7006.2010.01652.x","article-title":"Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation","volume":"101","author":"Takaishi","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib171","first-page":"999","article-title":"Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: A poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1","volume":"3","author":"Chambers","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib172","article-title":"The impact of the tumor microenvironment on macrophage polarization in cancer metastatic progression","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib173","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","article-title":"Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis","volume":"147","author":"Yuan","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib174","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s42003-020-01246-z","article-title":"Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1","volume":"3","author":"Krishnan","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib175","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib176","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3389\/fimmu.2019.00691","article-title":"Clinical relevance and immunosuppressive pattern of circulating and infiltrating subsets of myeloid-derived suppressor cells (MDSCs) in epithelial ovarian cancer","volume":"10","author":"Ok\u0142a","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib177","doi-asserted-by":"crossref","first-page":"76843","DOI":"10.18632\/oncotarget.20164","article-title":"Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(-\/low) myeloid-derived suppressor cells in ovarian cancer patients","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2022.03.027_bib178","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3389\/fimmu.2019.01273","article-title":"Myeloid derived suppressor cells: Key drivers of immunosuppression in ovarian cancer","volume":"10","author":"Baert","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib179","article-title":"Targeting myeloid-derived suppressor","volume":"10","author":"Mabuchi","year":"2021","journal-title":"Cells Ovarian Cancer Cells"},{"key":"10.1016\/j.semcancer.2022.03.027_bib180","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/0008-5472.CAN-14-1491","article-title":"l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells","volume":"75","author":"Fletcher","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib181","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1084\/jem.20181170","article-title":"Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum","volume":"216","author":"Lee","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib182","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijgo.12986","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy","volume":"148","author":"Salman","year":"2020","journal-title":"Int. J. Gynaecol. Obstet. Off. Organ Int. Fed. Gynaecol. Obstet."},{"key":"10.1016\/j.semcancer.2022.03.027_bib183","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2018.05.004","article-title":"Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients","volume":"150","author":"Baert","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib184","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5468\/ogs.2020.63.1.55","article-title":"Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy","volume":"63","author":"Jeerakornpassawat","year":"2020","journal-title":"Obstet. Gynecol. Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib185","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.it.2018.12.003","article-title":"The emergence of natural killer cells as a major target in cancer immunotherapy","volume":"40","author":"Souza-Fonseca-Guimaraes","year":"2019","journal-title":"Trends Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib186","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3389\/fimmu.2019.01782","article-title":"Naturally killing the silent killer: NK cell-based immunotherapy for ovarian cancer","volume":"10","author":"Nersesian","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib187","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: Natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib188","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","article-title":"Tumor-infiltrating natural killer cells","volume":"11","author":"C\u00f3zar","year":"2021","journal-title":"Cancer Disco"},{"key":"10.1016\/j.semcancer.2022.03.027_bib189","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nri2604","article-title":"Oncogenic stress sensed by the immune system: Role of natural killer cell receptors","volume":"9","author":"Raulet","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib190","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-3-030-17864-2_2","article-title":"MHC\/HLA Class I loss in cancer cells","volume":"1151","author":"Garrido","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib191","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","article-title":"Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer","volume":"20","author":"Webb","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib192","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/0284186X.2019.1711173","article-title":"Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma","volume":"59","author":"Henriksen","year":"2020","journal-title":"Acta Oncol. (Stockh. Swed. )"},{"key":"10.1016\/j.semcancer.2022.03.027_bib193","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.4049\/jimmunol.180.11.7338","article-title":"Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D","volume":"180","author":"Krockenberger","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib194","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2014.1001224","article-title":"B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape","volume":"4","author":"Pesce","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2022.03.027_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109632","article-title":"High-grade serous ovarian tumor cells modulate NK cell function to create an immune-tolerant microenvironment","volume":"36","author":"Gonzalez","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2022.03.027_bib196","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","article-title":"The extracellular matrix modulates the hallmarks of cancer","volume":"15","author":"Pickup","year":"2014","journal-title":"EMBO Rep."},{"key":"10.1016\/j.semcancer.2022.03.027_bib197","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cell.2009.10.027","article-title":"Matrix crosslinking forces tumor progression by enhancing integrin signaling","volume":"139","author":"Levental","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2022.03.027_bib198","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib199","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051532","article-title":"Fibroblasts in the tumor microenvironment: Shield or spear?","volume":"19","author":"Alkasalias","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib200","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.trecan.2020.03.001","article-title":"Drilling for oil: Tumor-surrounding adipocytes fueling cancer","volume":"6","author":"Attan\u00e9","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib201","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/2159-8290.CD-17-0284","article-title":"Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers","volume":"8","author":"Pearce","year":"2018","journal-title":"Cancer Disco"},{"key":"10.1016\/j.semcancer.2022.03.027_bib202","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/0008-5472.CAN-18-2616","article-title":"Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis","volume":"79","author":"Natarajan","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib203","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2016.04.038","article-title":"Tumor microenvironment: The culprit for ovarian cancer metastasis?","volume":"377","author":"Luo","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2022.03.027_bib204","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: Function and therapeutic strategy","volume":"8","author":"Yang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib205","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/s41467-021-24009-8","article-title":"Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance","volume":"12","author":"Pietil\u00e4","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.03.027_bib206","first-page":"M111","article-title":"The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices","volume":"014647","author":"Naba","year":"2012","journal-title":"Mol. Cell. Proteom. MCP 11"},{"key":"10.1016\/j.semcancer.2022.03.027_bib207","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-021-01103-4","article-title":"Spatial architecture of the immune microenvironment orchestrates tumor immunity and therapeutic response","volume":"14","author":"Fu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib208","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040626","article-title":"Emerging trends in neoadjuvant chemotherapy for ovarian cancer","volume":"13","author":"Patel","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2022.03.027_bib209","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib210","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-20-1602","article-title":"Replication gaps underlie BRCA deficiency and therapy response","volume":"81","author":"Panzarino","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib211","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2174\/1568009033481967","article-title":"Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action","volume":"3","author":"Abal","year":"2003","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.semcancer.2022.03.027_bib212","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: An NRG oncology\/gynecologic oncology group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib213","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.06.0376","article-title":"Intraperitoneal chemotherapy in ovarian cancer remains experimental","volume":"24","author":"Gore","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"Suppl 24","key":"10.1016\/j.semcancer.2022.03.027_bib214","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1002\/cncr.32496","article-title":"Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer","volume":"125","author":"Vergote","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib215","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib216","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib217","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib218","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib219","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41698-018-0063-0","article-title":"Tumor evolution and chemoresistance in ovarian cancer","volume":"2","author":"Kim","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib220","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib221","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib222","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib223","doi-asserted-by":"crossref","first-page":"383","DOI":"10.4252\/wjsc.v11.i7.383","article-title":"Presence and role of stem cells in ovarian cancer","volume":"11","author":"Kenda Suster","year":"2019","journal-title":"World J. Stem Cells"},{"key":"10.1016\/j.semcancer.2022.03.027_bib224","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.biocel.2018.12.010","article-title":"Ovarian cancer stem cells: What progress have we made?","volume":"107","author":"Al-Alem","year":"2019","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib225","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3389\/fonc.2020.00319","article-title":"Novel therapeutic strategies for ovarian cancer stem cells","volume":"10","author":"Terraneo","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib226","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071586","article-title":"The role of tumor microenvironment in chemoresistance: To survive, keep your enemies closer","volume":"18","author":"Senthebane","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2022.03.027_bib227","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1054\/bjoc.2001.1907","article-title":"Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer","volume":"85","author":"McFadyen","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib228","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bjc.2014.386","article-title":"Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines","volume":"111","author":"Sawers","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib229","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/jhg.2013.105","article-title":"Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients","volume":"58","author":"Hirasawa","year":"2013","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.semcancer.2022.03.027_bib230","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D\u2019Andrea","year":"2018","journal-title":"DNA Repair"},{"key":"10.1016\/j.semcancer.2022.03.027_bib231","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1054\/bjoc.2001.2037","article-title":"A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer","volume":"85","author":"Watanabe","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib232","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1477-7827-1-66","article-title":"Chemoresistance in human ovarian cancer: The role of apoptotic regulators","volume":"1","author":"Fraser","year":"2003","journal-title":"Reprod. Biol. Endocrinol. RBE"},{"key":"10.1016\/j.semcancer.2022.03.027_bib233","doi-asserted-by":"crossref","first-page":"17163","DOI":"10.1074\/jbc.M114.558288","article-title":"Role of autophagy in cisplatin resistance in ovarian cancer cells","volume":"289","author":"Wang","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2022.03.027_bib234","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1158\/1078-0432.CCR-04-0748","article-title":"Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells","volume":"10","author":"Holzer","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib235","first-page":"5853","article-title":"Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients","volume":"9","author":"Samimi","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib236","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ijc.10608","article-title":"Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP","volume":"101","author":"Nakayama","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib237","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/jcb.27681","article-title":"Extracellular matrix (ECM) stiffness and degradation as cancer drivers","volume":"120","author":"Najafi","year":"2019","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.semcancer.2022.03.027_bib238","article-title":"Longitudinal single-cell RNA-seq analysis reveals stress-promoted chemoresistance in metastatic ovarian cancer","volume":"8","author":"Zhang","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.semcancer.2022.03.027_bib239","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1158\/1541-7786.MCR-17-0338","article-title":"Adipocytes sequester and metabolize the chemotherapeutic daunorubicin","volume":"15","author":"Sheng","year":"2017","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.semcancer.2022.03.027_bib240","doi-asserted-by":"crossref","first-page":"14905","DOI":"10.18632\/oncotarget.3614","article-title":"Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes","volume":"6","author":"Alonso","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2022.03.027_bib241","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41571-018-0007-1","article-title":"Targeting the tumour stroma to improve cancer therapy","volume":"15","author":"Valkenburg","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib242","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911177","article-title":"Adaptive RSK-EphA2-GPRC5A signaling switch triggers chemotherapy resistance in ovarian cancer","volume":"12","author":"Moyano-Galceran","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib243","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13148-021-01178-3","article-title":"DNA methylation-based profiling reveals distinct clusters with survival heterogeneity in high-grade serous ovarian cancer","volume":"13","author":"Wang","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.semcancer.2022.03.027_bib244","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13148-021-01130-5","article-title":"Genome-wide DNA methylome analysis identifies methylation signatures associated with survival and drug resistance of ovarian cancers","volume":"13","author":"Chan","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.semcancer.2022.03.027_bib245","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13148-021-01105-6","article-title":"Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance","volume":"13","author":"Gallon","year":"2021","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.semcancer.2022.03.027_bib246","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050505","article-title":"Current status of patient-derived ovarian cancer models","volume":"8","author":"Maru","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.semcancer.2022.03.027_bib247","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.03.027_bib248","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.trecan.2020.07.007","article-title":"Human-derived model systems in gynecological cancer research","volume":"6","author":"L\u00f5hmussaar","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib249","doi-asserted-by":"crossref","first-page":"7419","DOI":"10.1038\/ncomms8419","article-title":"Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours","volume":"6","author":"Ince","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.03.027_bib250","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1158\/1078-0432.CCR-17-0133","article-title":"Personalized medicine-based approach to model patterns of chemoresistance and tumor recurrence using ovarian cancer stem cell spheroids","volume":"23","author":"Raghavan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib251","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2022.03.027_bib252","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses","volume":"31","author":"de Witte","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2022.03.027_bib253","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1158\/1535-7163.MCT-19-0052","article-title":"Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis","volume":"19","author":"Kenny","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.semcancer.2022.03.027_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102676","article-title":"A human multi-cellular model shows how platelets drive production of diseased extracellular matrix and tissue invasion","volume":"24","author":"Malacrida","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.semcancer.2022.03.027_bib255","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40425-019-0666-1","article-title":"Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments","volume":"7","author":"Raghavan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib256","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-3-030-73359-9_9","article-title":"3D models for ovarian cancer","volume":"1330","author":"Kast","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib257","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41378-020-00201-6","article-title":"A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies","volume":"6","author":"Dadgar","year":"2020","journal-title":"Microsyst. Nanoeng."},{"key":"10.1016\/j.semcancer.2022.03.027_bib258","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10544-013-9739-y","article-title":"An integrated microfluidic platform for rapid tumor cell isolation, counting and molecular diagnosis","volume":"15","author":"Hung","year":"2013","journal-title":"Biomed. Micro"},{"key":"10.1016\/j.semcancer.2022.03.027_bib259","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1039\/C9LC00979E","article-title":"An integrated microfluidic system for rapid, automatic and high-throughput staining of clinical tissue samples for diagnosis of ovarian cancer","volume":"20","author":"Huang","year":"2020","journal-title":"Lab a chip"},{"key":"10.1016\/j.semcancer.2022.03.027_bib260","doi-asserted-by":"crossref","DOI":"10.3791\/55337-v","article-title":"Modeling Ovarian Cancer Multicellular Spheroid Behavior in a Dynamic 3D Peritoneal Microdevice","author":"Li","year":"2017","journal-title":"J. Vis. Exp. JoVE"},{"key":"10.1016\/j.semcancer.2022.03.027_bib261","doi-asserted-by":"crossref","first-page":"153","DOI":"10.24272\/j.issn.2095-8137.2020.382","article-title":"Mouse models of epithelial ovarian cancer for preclinical studies","volume":"42","author":"Karakashev","year":"2021","journal-title":"Zool. Res."},{"issue":"525\u2013540","key":"10.1016\/j.semcancer.2022.03.027_bib262","article-title":"Mouse ovarian cancer models recapitulate the human tumor microenvironment and patient response to treatment","volume":"30","author":"Maniati","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2022.03.027_bib263","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-20-0818","article-title":"Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy","volume":"11","author":"Iyer","year":"2021","journal-title":"Cancer Disco"},{"key":"10.1016\/j.semcancer.2022.03.027_bib264","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024420","article-title":"Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis","volume":"6","author":"Bankert","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.semcancer.2022.03.027_bib265","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/17460441.2018.1426567","article-title":"The latest animal models of ovarian cancer for novel drug discovery","volume":"13","author":"Magnotti","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.semcancer.2022.03.027_bib266","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.19.00508","article-title":"Immunotherapy in ovarian Cancer: Are we there yet?","volume":"37","author":"Kandalaft","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib267","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ygyno.2018.10.008","article-title":"Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials","volume":"151","author":"Hinchcliff","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib268","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib269","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2022.03.027_bib270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","article-title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","volume":"25","author":"Scheper","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib271","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ygyno.2020.09.045","article-title":"Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape","volume":"160","author":"Blanc-Durand","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib272","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184553","article-title":"Integrating cancer vaccines in the standard-of-care of ovarian cancer: translating preclinical models to human","volume":"13","author":"Chiang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2022.03.027_bib273","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: A pilot study","volume":"7","author":"Pedersen","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.semcancer.2022.03.027_bib274","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2022.03.027_bib275","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12917","article-title":"SJI 2020 special issue: A catalogue of ovarian cancer targets for CAR therapy","volume":"92","author":"Benard","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib276","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","article-title":"Mesothelin-specific CAR T cells target ovarian cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib277","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1200\/JCO.21.00306","article-title":"Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib278","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib279","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib280","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: A phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib281","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ygyno.2019.02.011","article-title":"Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma","volume":"153","author":"Morse","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib282","first-page":"44","article-title":"Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer","volume":"26","author":"Hofheinz","year":"2003","journal-title":"Onkologie"},{"key":"10.1016\/j.semcancer.2022.03.027_bib283","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/ijc.32606","article-title":"Final results from GCIG\/ENGOT\/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer","volume":"146","author":"Ray-Coquard","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.semcancer.2022.03.027_bib284","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2010.12.362","article-title":"A phase II, single-arm study of the anti-\u03b15\u03b21 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer","volume":"121","author":"Bell-McGuinn","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib285","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1158\/1078-0432.CCR-06-2779","article-title":"Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors","volume":"13","author":"Mullamitha","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.03.027_bib286","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdh387","article-title":"Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas","volume":"15","author":"Faleiro-Rodrigues","year":"2004","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib287","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature16064","article-title":"Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer","volume":"527","author":"Zheng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2022.03.027_bib288","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nature15748","article-title":"Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance","volume":"527","author":"Fischer","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2022.03.027_bib289","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","article-title":"Guidelines and definitions for research on epithelial-mesenchymal transition","volume":"21","author":"Yang","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2022.03.027_bib290","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.633","article-title":"The multicellular signalling network of ovarian cancer metastases","volume":"11","author":"Sommerfeld","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.semcancer.2022.03.027_bib291","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00404-020-05477-7","article-title":"Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer","volume":"301","author":"Banys-Paluchowski","year":"2020","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.semcancer.2022.03.027_bib292","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2014.05.002","article-title":"Hematogenous metastasis of ovarian cancer: rethinking mode of spread","volume":"26","author":"Pradeep","year":"2014","journal-title":"Cancer Cell"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X22000839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X22000839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:49:36Z","timestamp":1778582976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X22000839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":292,"alternative-id":["S1044579X22000839"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.027","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2022.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}